DrugPatentWatch Database Preview
Selexipag - Generic Drug Details
What are the generic sources for selexipag and what is the scope of selexipag freedom to operate?
Selexipag
is the generic ingredient in one branded drug marketed by Actelion Pharms Ltd and is included in one NDA. There are four patents protecting this compound. Additional information is available in the individual branded drug profile pages.There is one drug master file entry for selexipag. One supplier is listed for this compound.
Summary for selexipag
| US Patents: | 4 |
| Tradenames: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Drug Master File Entries: | 1 |
| Suppliers / Packagers: | 1 |
| Bulk Api Vendors: | 38 |
| Clinical Trials: | 15 |
| Patent Applications: | 52 |
| DailyMed Link: | selexipag at DailyMed |
Pharmacology for selexipag
| Drug Class | Prostacyclin Receptor Agonist |
| Mechanism of Action | Prostacyclin Receptor Agonists |
Synonyms for selexipag
| 144383-EP2289518A1 |
| 144383-EP2292231A1 |
| 2-?[4-?[(5,?6-?DIPHENYLPYRAZINYL)(1-?METHYLETHYL)AMINO]BUTOXY]-?N-?(METHYLSULFONYL)-?ACETAMIDE |
| 2-(4-((5,6-diphenylpyrazin-2-yl)(isopropyl)amino)butoxy)-N-(methylsulfonyl)acetamide |
| 2-(4-((5,6-Diphenylpyrazin-2-yl)(propan-2-yl)amino)butoxy}-n-(methanesulfonyl)acetamide |
| 2-(4-((5,6-Diphenylpyrazinyl)(1-methylethyl)amino)butoxy)-N-(methylsulfonyl)-acetamide |
| 2-[4-[(5,6-Diphenyl-2-pyrazinyl)(1-methylethyl)amino]butoxy]-N-(methylsulfonyl)acetamide |
| 2-[4-[[5,6-di(phenyl)pyrazin-2-yl]-propan-2-ylamino]butoxy]-N-methylsulfonylacetamide |
| 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-(methanesulfonyl)acetamide |
| 2-{4-[(5,6-diphenylpyrazin-2-yl)(propan-2-yl)amino]butoxy}-N-methanesulfonylacetamide |
| 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsulfonyl)acetamide |
| 3938AH |
| 475086-01-2 |
| 5EXC0E384L |
| ACT 293987 |
| ACT-293987 |
| ACT293987 |
| AK298890 |
| AKOS024457572 |
| B7378 |
| CHEBI:90844 |
| CHEMBL238804 |
| CS-3774 |
| CTK8F0123 |
| D09994 |
| D0N2SR |
| DB11362 |
| GTPL7552 |
| HE092855 |
| HY-14870 |
| IN2104 |
| KB-79567 |
| KS-00000L89 |
| MFCD10567093 |
| MolPort-009-019-323 |
| NS 304 |
| NS-304 |
| NS-304(Selexipag) |
| QXWZQTURMXZVHJ-UHFFFAOYSA-N |
| RT-014761 |
| SCHEMBL674122 |
| Selexipag (JAN/USAN/INN) |
| Selexipag [USAN:INN] |
| UNII-5EXC0E384L |
| Uptravi |
| Uptravi (TN) |
| ZINC3990451 |
US Patents and Regulatory Information for selexipag
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-004 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-005 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-001 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-004 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-003 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-001 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ➤ Sign Up | ||||
| Actelion Pharms Ltd | UPTRAVI | selexipag | TABLET;ORAL | 207947-006 | Dec 21, 2015 | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | Y | Y | ➤ Sign Up | ||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
International Patents for selexipag
| Country | Document Number | Estimated Expiration |
|---|---|---|
| Russian Federation | 2283835 | ➤ Sign Up |
| World Intellectual Property Organization (WIPO) | 02088084 | ➤ Sign Up |
| Argentina | 073031 | ➤ Sign Up |
| China | 1301973 | ➤ Sign Up |
| Russian Federation | 2556206 | ➤ Sign Up |
| Russian Federation | 2003134190 | ➤ Sign Up |
| Taiwan | 201111352 | ➤ Sign Up |
| Country | Document Number | Estimated Expiration |
Supplementary Protection Certificates for selexipag
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| 2016000077 | Germany | ➤ Sign Up | PRODUCT NAME: SELEXIPAG ODER SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083/001-010 20160512 |
| 2016 00048 | Denmark | ➤ Sign Up | PRODUCT NAME: SELEXIPAG ELLER ET SALT DERAF; REG. NO/DATE: EU/1/15/1083 20160519 |
| 16/047 | Ireland | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OR SALT THEREOF; REGISTRATION NO/DATE: EU/1/15/1083 20160512 |
| 90044-1 | Sweden | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OR SALT THEROF; REG. NO/DATE: EU/1/15/1083 20160519 |
| 266 | Luxembourg | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OU UN SEL DE CELUI-CI; FIRST REGISTRATION DATE: 20160519 |
| /2016 | Austria | ➤ Sign Up | PRODUCT NAME: SELEXIPAG ODER EIN SALZ DAVON; REGISTRATION NO/DATE: EU/1/15/1083 (MITTEILUNG) 20160519 |
| C0042 | France | ➤ Sign Up | PRODUCT NAME: SELEXIPAG OU L'UN DE SES SELS; REGISTRATION NO/DATE: EU/1/15/1083 20160519 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
For more information try a trial or see the plans and pricing
Serving hundreds of leading biopharmaceutical companies globally:
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
Major Patent Expirations 2018 - 2019
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2018, www.DrugPatentWatch.com.
Follow DrugPatentWatch: